Related Experiment Video
Updated: Sep 18, 2025
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Research Progress in Targeting GSPT1: Molecular Glues, Bifunctional Degraders, and Antibody-Enabled Molecular Glues
Binbin Cheng1,2, Yaping Wang2, Yimeng Hong2
1Central Laboratory, Wenzhou Medical University Lishui Hospital, Lishui People's Hospital, Lishui, Zhejiang 323000, China.
Abstract:
G1 to S phase transition 1 (GSPT1, also known as eRF3a) is a crucial translation termination factor that plays a vital role in acute myeloid leukemia (AML) and MYC-driven lung cancer. Degrading GSPT1 can induce apoptosis in cancer cells and reduce their viability, thus making GSPT1 a potential therapeutic target. This perspective aims to introduce the current research status of the mechanism of molecular glues targeting GSPT1, summarize the recent progress in and challenges for existing molecular glues, bifunctional degraders, and antibody-enabled molecular glues targeting GSPT1, and outline the development strategies for targeting GSPT1 in the treatment of cancer.
Insights
Targeting G1 to S phase transition 1 (GSPT1) protein degradation shows promise for treating acute myeloid leukemia and MYC-driven lung cancer. This review explores molecular glues and degraders for GSPT1, offering strategies for cancer therapy development.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- G1 to S phase transition 1 (GSPT1), also known as eRF3a, is a key translation termination factor.
- GSPT1 is implicated in the pathogenesis of acute myeloid leukemia (AML) and MYC-driven lung cancers.
- Targeting GSPT1 for degradation presents a potential therapeutic strategy due to its role in cancer cell survival.
Purpose of the Study:
- To review the mechanisms of molecular glues targeting GSPT1.
- To summarize recent advancements and challenges in developing molecular glues, bifunctional degraders, and antibody-enabled molecular glues for GSPT1.
- To outline strategies for developing GSPT1-targeted cancer therapies.
Main Methods:
- Literature review of current research on GSPT1 molecular glues and degraders.
- Analysis of existing therapeutic approaches and their limitations.
- Exploration of future development strategies for GSPT1-targeted cancer treatment.
Main Results:
- Molecular glues and bifunctional degraders are emerging as effective strategies to induce GSPT1 degradation.
- Antibody-enabled molecular glues offer targeted delivery and enhanced efficacy.
- Challenges include optimizing drug specificity, delivery, and overcoming resistance mechanisms.
Conclusions:
- GSPT1 is a viable therapeutic target for AML and MYC-driven lung cancer.
- Novel molecular glue and degrader technologies show significant potential for cancer treatment.
- Further research and development are needed to translate these findings into effective clinical therapies.
